TRex Bio (NASDAQ:TRXB) Now Covered by Stifel Nicolaus

Equities research analysts at Stifel Nicolaus began coverage on shares of TRex Bio (NASDAQ:TRXB) in a research note issued to investors on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $39.00 price target on the stock. Stifel Nicolaus‘s price target indicates a potential upside of 185.92% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. assumed coverage on TRex Bio in a report on Tuesday. They set an “overweight” rating and a $20.00 target price on the stock. Wedbush started coverage on TRex Bio in a report on Monday. They issued an “outperform” rating and a $30.00 price target for the company. Four investment analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, TRex Bio currently has an average rating of “Buy” and an average target price of $29.67.

TRex Bio Trading Down 0.7%

Shares of TRex Bio stock opened at $13.64 on Tuesday. TRex Bio has a 1 year low of $13.10 and a 1 year high of $16.56.

Insider Activity

In other news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the acquisition, the insider directly owned 1,346,501 shares in the company, valued at $18,851,014. This represents a 15.29% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.